The dearth of documented consensual clinicopathological characterization of Taiwanese patients with DHL/THL, otherwise designated high-grade B-cell lymphoma (HGBL) with MYC and BCL2 and/or BCL6 rearrangements [14,15], informs the present study. The gene discussed is MYC; the disease is B-cell non-Hodgkin lymphoma.